Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2009-07-23 Share Issue/Capital Cha…
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Exercise of Employee Options 10 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to new securities issuance and quotation. It details the issuance of fully paid ordinary shares upon exercise of options under an Employee Option Plan, including number of securities, exercise prices, and terms. The document is a formal announcement to the ASX regarding the new issue of shares and application for quotation of additional securities. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a regulatory announcement specifically about new share issuance and quotation. Therefore, the document fits the category of Share Issue/Capital Change (SHA). The document length is over 14,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement. Confidence is high due to clear identification of the document type and content.
2009-07-23 English
Quarterly Report to Shareholders June 2009 8 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Report to Shareholders' and covers the period April to June 2009, indicating it is a quarterly report. It contains detailed information on clinical trials, product development, regulatory updates, marketing activities, financial highlights such as capital raised, and operational updates. The length is substantial (15,000 characters), and it includes substantive financial and operational data rather than just an announcement or summary. There is no indication that this is an annual report or an earnings release with only key highlights. The content fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements or substantive financial data and analysis. Q2 2009
2009-07-21 English
Appendix 4C - Quarterly Cash Flow 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed consolidated cash flow statements, financing activities, reconciliation of cash, and compliance statements for the quarter ended 30 June 2009. It includes substantive financial data and analysis for a quarterly period, consistent with regulatory requirements for quarterly reporting. The document is approximately 8,245 characters long, which is sufficient to be a full report rather than a brief announcement. The content aligns with the characteristics of an Interim / Quarterly Report (IR) as it provides comprehensive financial information for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or certification, nor does it fit other categories such as Earnings Release or Regulatory Filings. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2009
2009-07-21 English
Investor Conference Call Presentation 17 pages ?Kb
Investor Presentation Classification · 95% confidence The document is an investor presentation from July 2009 by Pharmaxis, focusing on therapeutic products for respiratory diseases, clinical trial phases, operational highlights, market research, and commercialization timetables. It contains forward-looking statements, detailed clinical trial data, market sizing, and manufacturing capacity information. There is no indication that this is a formal regulatory filing like a 10-K or interim report, nor is it an earnings release or audit report. The content is typical of an investor presentation aimed at providing detailed financial, strategic, and operational information to investors. The length (over 13,000 characters) and detailed content support this classification. Therefore, the document best fits the category of Investor Presentation (IP).
2009-07-21 English
Pharmaxis Investor Conference Call 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX media release announcing an upcoming investor conference call to discuss the June 2009 Quarterly Report. It provides details about the teleconference timing, access numbers, and mentions that the quarterly report will be released the day before the call. The document itself does not contain the quarterly report or substantive financial data, but rather serves as an announcement for the call and report release. According to the 'Menu vs Meal' rule, this is not the report itself but an announcement related to it. The document is a Call Transcript announcement or invitation, but since it is prior to the call and not a transcript, it fits best as a Regulatory Filing (RNS) or possibly an Investor Presentation (IP). However, since it is a media release announcing a conference call and report release, the best fit is Regulatory Filings (RNS).
2009-07-20 English
Pharmaxis to Voluntarily De-List from Nasdaq 1 page
Delisting Announcement Classification · 100% confidence The document is a media release dated 13 July 2009 from Pharmaxis announcing its decision to voluntarily de-list from the Nasdaq Global Market. It details the process and timeline for de-listing, including filing Form 25 and Form 15F with the SEC, and the continuation of its primary listing on the Australian Securities Exchange. The document is an official notice about the company's stock being removed from an exchange, which matches the definition of a Delisting Announcement. The document length is 3419 characters, which is short but contains substantive information about the delisting event itself, not just a notice of report publication. Therefore, the correct classification is Delisting Announcement (DLST).
2009-07-12 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.